Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 14/20 | 0.57 |
| ▸ | MMP9 | P14780 | 14/20 | 0.57 |
| ▸ | MMP13 | P45452 | 5/20 | 0.57 |
| ▸ | MMP1 | P03956 | 3/20 | 0.57 |
| ▸ | MMP3 | P08254 | 3/20 | 0.57 |
| ▸ | MMP7 | P09237 | 3/20 | 0.57 |
| ▸ | MMP12 | P39900 | 8/20 | 0.52 |
| ▸ | MMP8 | P22894 | 6/20 | 0.52 |
| ▸ | MMP14 | P50281 | 6/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7346447 | 0.97 | MMP2 (0.59) | MMP2MMP9MMP13MMP1MMP3 | |
| SCHEMBL7346134 | 0.94 | MMP2 (0.60) | MMP2MMP9MMP13MMP1MMP3 | |
| SCHEMBL7344211 | 0.94 | MMP2 (0.65) | MMP2MMP9MMP13MMP1MMP3 | |
| SCHEMBL7349914 | 0.91 | MMP13 (0.58) | MMP2MMP9MMP13MMP1MMP3 | |
| SCHEMBL7352707 | 0.90 | MMP13 (0.59) | MMP2MMP9MMP13MMP1MMP3 | |
| SCHEMBL7351411 | 0.89 | MMP2 (0.54) | MMP2MMP9MMP13MMP1MMP3 | |
| SCHEMBL7352548 | 0.89 | MMP12 (0.53) | MMP2MMP9MMP13MMP1MMP3 | |
| SCHEMBL7349613 | 0.88 | MMP2 (0.58) | MMP2MMP9MMP13MMP1MMP3 | |
| SCHEMBL7347931 | 0.88 | MMP2 (0.58) | MMP2MMP9MMP13MMP1MMP3 | |
| SCHEMBL7349030 | 0.88 | MMP2 (0.58) | MMP2MMP9MMP13MMP1MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6294674-B1 | FOR THERAPY OF MULTIPLE SCLEROSIS, ATHEROSCLEROTIC PLAQUE RUPTURE, RESTENOSIS, AORTIC ANEURISM, HEART FAILURE, PERIODONTAL DISEASE, CORNEAL ULCERATION, BURNS, DECUBITAL ULCERS, CHRONIC ULCERS OR WOUNDS, CANCER METASTASIS | WARNER-LAMBERT COMPANY | 2001-09-25 | — | — | US | claimed |
| EP-0929542-A1 | COMPOUNDS FOR AND A METHOD OF INHIBITING MATRIX METALLOPROTEINASES | WARNER-LAMBERT COMPANY (US) | 1999-07-21 | — | — | EP | claimed |
| WO-1998009957-A1 | COMPOUNDS FOR AND A METHOD OF INHIBITING MATRIX METALLOPROTEINASES | WARNER-LAMBERT COMPANY (US) | 1998-03-12 | — | — | WO | claimed |
| US-6294674-B1 | FOR THERAPY OF MULTIPLE SCLEROSIS, ATHEROSCLEROTIC PLAQUE RUPTURE, RESTENOSIS, AORTIC ANEURISM, HEART FAILURE, PERIODONTAL DISEASE, CORNEAL ULCERATION, BURNS, DECUBITAL ULCERS, CHRONIC ULCERS OR WOUNDS, CANCER METASTASIS | WARNER-LAMBERT COMPANY | 2001-09-25 | — | — | US | disclosed |
| EP-0929542-A1 | COMPOUNDS FOR AND A METHOD OF INHIBITING MATRIX METALLOPROTEINASES | WARNER-LAMBERT COMPANY (US) | 1999-07-21 | — | — | EP | disclosed |
| WO-1998009957-A1 | COMPOUNDS FOR AND A METHOD OF INHIBITING MATRIX METALLOPROTEINASES | WARNER-LAMBERT COMPANY (US) | 1998-03-12 | — | — | WO | disclosed |